Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

Medicare Is About to Cover Weight-Loss Drugs for the First Time — Here's What the GLP-1 Bridge Program Means for Millions of Americans with Obesity

Medicare's GLP-1 Bridge launches July 1, 2026, offering eligible Part D enrollees Wegovy and Zepbound for $50/month — the first-ever Medicare coverage for obesity-specific GLP-1 drugs.

From Crisis to Possible Cure Path: San Antonio Battles Highest Diabetes Rates as Wegovy and Medicare (United States) Expansion Offer New Hope

From Crisis to Possible Cure Path: San Antonio Battles Highest Diabetes Rates as Wegovy and Medicare (United States) Expansion Offer New Hope

Diabetes care is entering a new era in San Antonio as the Wegovy pill and expanded Medicare coverage offer new hope for preventing and managing diabetes in one of America's hardest-hit cities.

5 Best Growth Stocks for the Next 10 Years

5 Best Growth Stocks for the Next 10 Years

These 5 long-term growth stocks could benefit from AI, cybersecurity, GLP-1 drugs, and fintech trends over the next decade

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Novo Nordisk uses AI to fast-track drug launches, expand India role

Novo Nordisk is leveraging Artificial Intelligence to significantly speed up new drug launches. The company expects to cut down the time to market by as much as two-thirds. Its center in Bengaluru, India, is becoming crucial for global drug preparations.

The Economic Times

The Silver Lining of Last Week's Hims & Hers Earnings Miss

Hims & Hers plunged 23% after a major Q1 earnings miss, but long-term growth stays intact via its Novo Nordisk GLP-1 partnership and a late 2026 expansion.

Singapore Court of Appeal Notes No Finding of Fraud Against KBP or Dr. Huang; Dispute with Novo Nordisk Undergoing Arbitration Proceedings

SINGAPORE, May 21, 2026 /PRNewswire/ -- KBP Biosciences Pte. Ltd. (the "Company" or "KBP") today issued a statement addressing the decision by the Singapore Court of Appeal to maintain the temporary injunction against the Company and its founder, Dr. Huang Zhenhua ("Dr. Huang"), pending final resolution of the arbitration proceedings…

CEOs are getting ruthless about worker performance

Corporate leaders are increasingly prioritizing results over employee comfort, with CEOs like Unilever's Fernando Fernandez demanding "volume growth, positive mix, consistent growth margin expansion." This shift towards "performance cultures" involves tougher accountability, potential layoffs, and a focus on tangible outcomes, signaling a departure from the more empathetic approach of the…

The Economic Times

inkl

Read news from The Economist, FT, and more,
with one subscription

This Hot Weight-Loss Drug Stock May Be a Surprise Challenger

This Hot Weight-Loss Drug Stock May Be a Surprise Challenger

The race to dominate the weight-loss drug market is heating up, and investors should start watching this one smaller player closely.

Hims & Hers Bets Big on GLP-1 Drugs, But Investors Want Profits Now

Hims & Hers Bets Big on GLP-1 Drugs, But Investors Want Profits Now

Hims & Hers delivered a sharp earnings miss as GLP-1 and international expansion costs surged. Investors now face a classic tradeoff between near-term margins and long-term growth.

Dr. Reddy's Laboratories Q4 Earnings Call Highlights

Dr. Reddy's Laboratories (NYSE:RDY) reported what Chief Financial Officer M.V. Narasimham described as a resilient FY 2026 performance, with record annual revenue despite pressure from lower lenalidomide sales and several one-time charges during the fourth quarter. Narasimham said the company’s und

Omeros Q1 Earnings Call Highlights

Omeros (NASDAQ:OMER) reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA, its recently approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA. Chairman and Chief Executive

Novo Nordisk A/S Q1 Earnings Call Highlights

Novo Nordisk A/S (NYSE:NVO) said its first quarter of 2026 was marked by rapid uptake of its newly launched Wegovy pill in the U.S., continued expansion of its obesity franchise and a series of pipeline and regulatory milestones, even as adjusted sales declined because of lower realized prices. Chi

Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?

Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?

Hims & Hers Health posted a Q1 FY2026 double miss, with an EPS loss of $0.40 and revenue of $608.1 million, sending shares down more than 12% after hours.

Mark Zuckerberg backed-Cellular Intelligence acquires Novo Nordisk's Parkinson's cell therapy

Mark Zuckerberg backed-Cellular Intelligence acquires Novo Nordisk's Parkinson's cell therapy

Last October, Novo Nordisk had shut down its cell therapy unit as part of a broader restructuring, discontinuing development ‌of ⁠the therapy.

The Economic Times

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Novo Nordisk boosted as sales of Wegovy weight loss pills soar

Evening Standard

Wegovy maker Novo Nordisk boosted by successful weight loss pill launch

The launch in January came amid a battle in the market with Mounjaro manufacturer Eli Lilly.

The Independent UK

Novo Nordisk shares soar as sales of Wegovy weight loss pill smash forecasts

The launch in January came amid a battle in the market with Mounjaro manufacturer Eli Lilly

Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent

Eli Lilly's 2026 is off to a great start, with massive earnings and revenue beats and exciting updates about its latest GLP-1, Foundayo.

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times UK

Hershey's CEO Claims Ozempic Breath is Driving Massive Surge in Mint and Gum Sales Across the United States

Hershey's CEO attributes an 8% sales increase in Ice Breakers mints and gum to the side effects of GLP-1 weight-loss drugs, highlighting an unexpected revenue driver.

The Independent UK

Trump team delays pilot program for Medicare to cover cost of ‘fat shot’

Without insurance or discounts, GLP-1 injectables can cost more than $1,000 per month

3 Ways to Invest in the Growing GLP-1 Weight Loss Market

GLP-1 drugs are big business, and investors can win rewards by searching beyond the biggest names or diversifying via ETFs.

What to know about OpenAI's new model for life sciences research GPT-Rosalind

The GPT-Rosalind model is designed to accelerate biological research and drug discovery.

The Independent UK

FDA asks drugmaker Eli Lilly for more safety information on its new GLP-1 weight loss pill

At the heart of the request is whether taking Foundayo - made with a new active ingredient called orforglipron - could be linked to liver, heart and gastrointestinal problems

The Independent UK

Wegovy maker announces partnership with OpenAI

The Independent UK

Wegovy maker and OpenAI partnering to speed up search for new drugs

The Danish drug manufacturer announced the partnership Tuesday, noting that the goal was to bring ‘new and better treatment options to patients faster’

1 2 3 4 5

People

194,397 stories

Mark Zuckerberg

Philipp Navratil

Fernando Fernandez

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

The Independent

Court of Appeal

the Court of Appeal

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

382,698 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play